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Increased survival of cirrhotic patients with septic
shock
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Alain Cariou1,2,3, Jean-Daniel Chiche1,2,4, Vincent Mallet2,4,5, Jean-Paul Mira1,2,4 and Frédéric Pène1,2,4*
Abstract
Introduction: The overall outcome of septic shock has been recently improved. We sought to determine whether
this survival gain extends to the high-risk subgroup of patients with cirrhosis.
Methods: Cirrhotic patients with septic shock admitted to a medical intensive care unit (ICU) during two
consecutive periods (1997-2004 and 2005-2010) were retrospectively studied.
Results: Forty-seven and 42 cirrhotic patients presented with septic shock in 1997-2004 and 2005-2010,
respectively. The recent period differed from the previous one by implementation of adjuvant treatments of septic
shock including albumin infusion as fluid volume therapy, low-dose glucocorticoids, and intensive insulin therapy.
ICU and hospital survival markedly improved over time (40% in 2005-2010 vs. 17% in 1997-2004, P = 0.02 and 29%
in 2005-2010 vs. 6% in 1997-2004, P = 0.009, respectively). Furthermore, this survival gain in the latter period was
sustained for 6 months (survival rate 24% in 2005-2010 vs. 6% in 1997-2004, P = 0.06). After adjustment with age,
the liver disease stage (Child-Pugh score), and the critical illness severity score (SOFA score), ICU admission
between 2005 and 2010 remained an independent favorable prognostic factor (odds ratio (OR) 0.09, 95%
confidence interval (CI) 0.02-0.4, P = 0.004). The stage of the underlying liver disease was also independently
associated with hospital mortality (Child-Pugh score: OR 1.42 per point, 95% CI 1.06-1.9, P = 0.018).
Conclusions: In the light of advances in management of both cirrhosis and septic shock, survival of such patients
substantially increased over recent years. The stage of the underlying liver disease and the related therapeutic
options should be included in the decision-making process for ICU admission.
Introduction
The overall incidence of severe sepsis and septic shock
is steadily increasing due to the aging of the population
and to the growing prevalence of underlying co-morbid-
ities including chronic organ dysfunctions and immuno-
suppression [1,2]. Several studies have highlighted the
major influence of cirrhosis on the susceptibility to
severe bacterial infections [3,4]. Indeed, the overall mor-
tality rate of septic shock remains particularly high in
cirrhotic patients, ranging from 60% to 100% [5-7], rais-
ing the question of indications of aggressive and exten-
sive organ failure support in such patients.
The overall outcome of septic shock has clearly
improved over the recent years, related to improved sup-
portive care and rapid and protocolized treatment inter-
ventions supported by international guidelines [8]. Of
note, the most significant improvements in survival from
septic shock have been achieved in vulnerable subgroups
including elderly patients, those with malignancies [9,10]
or neutropenia [11]. Cirrhotic patients are usually
excluded from interventional trials in sepsis, but it is likely
that such a high-mortality subgroup would particularly
benefit from therapeutic advances in septic shock. In addi-
tion, great strides have also been recently achieved in the
management of specific complications of cirrhosis.
Whether the survival gain achieved by therapeutic
advances in septic shock also extends to cirrhotic patients
has not been assessed. In order to determine the trend in
mortality of cirrhotic patients with septic shock and the
impact of related therapeutic interventions, we performed
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a retrospective single-center study over a 14-year time
period.
Materials and methods
Patients and setting
The study took place in a 24-bed medical ICU with an
average of 1,500 admissions per year. All patients with his-
tological or clinical diagnosis of cirrhosis and presenting
with septic shock at the time of ICU admission or within
the first 48 h in the ICU were included. Septic shock was
defined as a microbiologically proven or clinically sus-
pected infection, associated with acute circulatory failure
requiring vasoactive support despite adequate fluid filling
[12]. Senior staffing remained quite stable over the 14-year
study period. ICU admission decisions were taken on by
both the intensivist and the referring hepatologist
throughout the study period. Therefore, only patients with
end-stage liver disease declined for liver transplantation
were not admitted to the ICU. End-of-life decisions to
withhold or withdraw life support were taken on collec-
tively when all participants were convinced that mainte-
nance or increase of life-sustaining therapies was futile
and that death would irremediably occur in a short-term
manner.
Informed consent was waived since the study was ret-
rospective and observational, in accordance with French
regulation of clinical research. This epidemiologic study
did not require ethical approval, in accordance with the
standards of our local institutional review board.
Intended care for cirrhotic patients with septic shock
Systematic screening for infection included clinical fea-
tures (temperature, signs of shock), biological para-
meters (leukocytes), chest X-rays, and cultures of blood,
sputum, urine, and ascites. As soon as infection was
recognized, patients were promptly treated with empiri-
cal broad-spectrum antibiotic combination, depending
on the site of infection, known colonization and pre-
vious antibiotic treatment. Antifungal therapy was added
if fungal infection was suspected or documented. Anti-
microbial treatment was narrowed after identification of
the responsible pathogen. In addition, source control
measures, such as surgery or removal of infected cathe-
ters were applied when necessary. Hemodynamic man-
agement included fluid resuscitation combined with
continuous infusion of vasoactive drugs (mostly norepi-
nephrin, while associated cardiac dysfunction prompted
the use of either a combination of norepinephrin and
dobutamine or epinephrin). Terlipressin was not used in
combination with other vasoactive drugs. Endotracheal
intubation and mechanical ventilation were performed
in case of respiratory failure or coma. Renal replacement
therapy (RRT), through either intermittent hemodialysis
or continuous venovenous hemofiltration was initiated
in case of acute renal failure, severe metabolic acidosis,
or other life-threatening metabolic disorders.
Several adjuvant therapies were progressively imple-
mented in septic patients over the study period. Thus,
patients with acute respiratory distress syndrome
(ARDS) were mechanically ventilated using a protective
strategy with low tidal volume of 6 mL/kg of predicted
body weight [13]. More generally, the plateau pressure
was limited to 30 cm H2O in all ventilated patients.
Intensive insulin therapy was used to maintain blood
glucose between 4.4 and 8.1 mmol/L [14]. Low-dose
corticosteroids (200 mg hydrocortisone per day) were
administrated in vasopressor-dependent septic shock for
5 to 7 days [15]. Patients with at least two organ dys-
functions were considered for treatment with activated
protein C in the absence of contraindication [16]. In
order to assess whether these therapeutic advances
resulted in improved survival in cirrhotic septic patients,
we divided the whole cohort in two near-sized period
groups, 1997-2004 (first period) and 2005-2010 (second
period), in between the first guidelines of the Surviving
Sepsis Campaign were published.
Data collection
The following data were collected: demographic charac-
teristics; Charlson co-morbidity index (excluding points
for liver disease) [17]; functional status prior to ICU
admission as assessed by the Knaus scale (A, prior good
health, no functional limitation; B, mild to moderate
limitation of activity because of a chronic disease; C,
serious but not incapacitating restriction of activity; D,
severe restriction of activity, including bedridden or
institutionalized persons) [18]; stage of cirrhosis graded
using the Child-Pugh classification [19]; and the Model
for End-stage Liver Disease (MELD) score [20]. Child-
Pugh score was computed prior to the current acute
complication whereas MELD score was computed on
the first day in the ICU. We also collected the infection
characteristics including microbiological and clinical
documentation and adequacy of initial antibiotic regi-
men within the early 48 h following the onset of infec-
tion, the organ failures supports including type and
volume of fluid loading, mechanical ventilation and
RRT, as well as adjuvant treatments of sepsis (intensive
insulin therapy, low-dose glucocorticoids and activated
protein C). The Simplified Acute Physiology Score 2
(SAPS II) and the Sequential Organ Failure Assessment
(SOFA) score were calculated on the first day in the
ICU [21,22]. Outcomes were in-ICU, in-hospital, and 6-
month survival rates. Vital status was assessed using the
medical records or the administrative hospital database.
The outcome of patients followed up in another hospital
or discharged home was requested to their referring
hepatologist or their general practitioner.
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Statistical analysis
Results are reported as median (25th-75th percentile) or
number (%) as appropriate. Categorical variables were
compared with c2 or Fisher exact tests, and continuous
variables were compared with the Mann-Whitney U test.
Survival curves were obtained using the Kaplan-Meier
method and compared using the log-rank test. To identify
characteristics associated with hospital mortality, we used
a logistic regression model. Variables that reached a
P value < 0.1 were entered into a multivariate analysis.
Inclusion of severity scores in the analysis precluded the
inclusion of related variables in order to avoid colinearity.
The goodness-of-fit of the model was evaluated by the
Hosmer-Lemeshow statistic. Odds ratios (OR) and their
95% confidence intervals (CI) were computed. All test
were two-sided and P values < 0.05 were considered statis-
tically significant. All calculations were performed with
SPSS software version 16 (SPSS, Chicago, IL, USA).
Results
Patients characteristics
During the 14-year study period, 1,632 patients with septic
shock were admitted to the ICU, including 89 patients
(5.5%) with cirrhosis. Among them, 47 patients were
admitted to the ICU during the first period (1997-2004)
whereas 42 were admitted during the latter (2005-2010)
(Figure 1). Underlying characteristics of patients are pre-
sented in Table 1 and were grossly similar between both
study periods. Most cirrhosis was caused by chronic alco-
hol abuse associated or not with chronic viral hepatitis B
or C infection. None of the patients presented with acute
alcoholic hepatitis. Six patients had hepatocellular carci-
noma, at an early stage (stage A, n = 2) or at an inter-
mediate stage (stage B, n = 4), according to the BCLC
classification [23].
The main sites of infections were pneumonia (42%),
spontaneous or secondary peritonitis (29%), and urinary
tract infection (11%). Sixty-nine patients (78%) had micro-
biologically documented infections balanced between
gram-positive cocci (31%) and gram-negative bacilli (31%)
(Table 1). Multi-drug resistant bacteria were more fre-
quently involved in the recent period (Table 1).
Management of organ failures
Major differences were noted in the management of
septic shock between both study periods, including type
and volumes of fluid loading within the first 3 days, ven-
tilatory management, and adjuvant therapies of sepsis
Figure 1 Flow chart of the study.
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Table 1 Baseline characteristics of patients.
Characteristic 1997-2004
47 patients
2005-2010
42 patients
P
Age (years, IQR) 55 (46.5-62) 58 (53-65) 0.08
Male gender 36 (76.5) 26 (62) 0.49
Knaus scale 0.15
Mild limitation (B) 6 (12.8) 10 (23.8)
Important limitation (C) 25 (53.2) 17 (40.5)
Severe limitation (D) 16 (34) 15 (35.7)
Charlson score (IQR)a 1 (0-1) 1 (0-2) 0.51
Co-morbidities
Chronic heart failure 4 (8.5) 3 (7) 0.81
COPD 2 (4.3) 3 (7) 0.79
Diabetes 6 (12.8) 10 (24) 0.27
Cancer 8 (17) 8 (19) 0.80
Hepatocellular carcinoma 3 3
Otherb 5 5
Immunosuppressionc 6 (12.8) 2 (4.8) 0.27
Cause of cirrhosisd
Alcohol +/- virus 38 (80.1) 34 (80.1) 1
Chronic Hepatitis B virus infection 2 (4.3 ) 0 0.50
Chronic Hepatitis C virus infection 6 (12.8) 4 (9.5) 0.74
Primary biliary cirrhosis 2 (4.3) 2 (4.8) 1
Undetermined 3 (6.4) 2 (4.8) 1
Persistent alcohol abuse 26 (55.3) 22 (52.3) 0.83
Nosocomial septic shock 13 (27.7) 14 (33.3) 0.67
Primary source of infection
Respiratory 18 (38.3) 19 (45.2) 0.53
Abdominal 10 (21.3) 16 (38,1) 0.10
Spontaneous peritonitis 8 (17) 14 (33.3)
Secondary peritonitis 2 (4.3) 2 (4.8)
Urinary tract 6 (12.8) 4 (9.5) 0.49
Others
CNS 3 (6.4) 0 0.10
Arthritis 1 (2.1) 1(2.4) 1
Isolated bacteriemia 2 (4.2) 0 0.50
Unknown 7 (14.9) 2 (4.8) 0.16
Bacteremia 20 (42.6) 14 (33.3) 0.39
Type of organisms
Gram-positive cocci 15 (31.9) 13 (30.9) 1
Gram-negative bacilli 17 (36.2) 11 (23.8) 0.25
Fungi 2 (4.3) 2 (4.8) 1
Culture negative 12 (25.5) 8 (19) 0.61
Polymicrobial sepsis 1 (2.1) 8 (19) 0.01
Multi-drug resistant bacteria 2 (4.3) 8 (17) 0.04
Variables are expressed as number (percentage) or median (interquartile range (IQR)). aExcluding liver disease points.
bBreast cancer (n = 3), colon cancer (n = 2), laryngeal cancer (n = 2), cholangiocarcinoma (n = 1), bladder cancer (n = 1), myeloma (n = 1).
cInfection by human immunodeficiency virus (n = 2), multiple myeloma (n = 1), hypogammaglobulinemia (n = 1), treatment with mesalazine (n = 1) and recent
chemotherapy for cancer (n = 3).
dSum of causes may exceed the number of patients because of concomitant alcoholic and viral cirrhosis.
CNS, Central Nervous System; COPD, Chronic Pulmonary Obstructive Disease.
Sauneuf et al. Critical Care 2013, 17:R78
http://ccforum.com/content/17/2/R78
Page 4 of 10
(Table 2). Indeed, intravenous albumin was frequently
used in the most recent period (57.1% of patients vs. 8.5%,
P < 0.001) whereas infusion of crystalloids was markedly
reduced in the same time (3 (1.7-4.5) L vs. 6 (3-8.9) L, P <
0.001). Moreover, albumin-resuscitated patients tended to
receive a higher albumin dose during the recent period
(50 (30-72.5) vs. 20 (17.5-30) g, P = 0.06). RRT was less
frequently required in the recent period (52.4 vs. 72.3%,
P = 0.08). The ventilatory management also significantly
differed between the two periods with smaller tidal
volumes used in the period 2005-2010 (8.6 vs. 7 mL/kg,
P = 0.001). Intensive insulin therapy and low-dose glu-
cocorticoids were also more frequently used in the second
period (83.3% vs. 31.9%, P < 0.001 and 81% vs. 44.7,
Table 2 Organ failures, ICU management, and outcome.
Characteristic 1997-2004
47 patients
2005-2010
42 patients
P
Scoring systems (IQR)
Child-Pugh score 9 (7-11) 10 (8.25-11) 0.22
MELD day 1 25 (17-33.8) 26 (20.2-32.8) 0.43
SAPS II day 1 56 (38-70.5) 59 (42-76) 0.10
SOFA day 1 14 (8.5-17.5) 13 (9-15) 0.18
Biological findings at ICU admission (IQR)
Serum creatinine level, μmol/L 140 (96-199) 147 (105-235) 0.93
Serum bilirubin level, μmol/L 48 (35-110) 68 (44.2-140.5) 0.23
Arterial blood lactate level, mmol/L 4.2 (2-6.5) 4.3 (2.2-7.9) 0.68
Serum sodium, mmol/L 134 (130.5-139) 135.5 (129.2-139) 0.74
Serum protein level, g/L 54 (44.5-61) 59 (50-66.8) 0.05
Factor V, % 42 (33-64) 46 (33-60) 0.70
INR 2 (1.5-2.8) 2 (1.6-3.1) 0.69
White blood cells, 103/mm3 13.6 (6.2-19) 10.7 (6.4-15.2) 0.45
C-reactive protein, mg/L 101 (60-167) 75 (34-127) 0.24
Mechanical ventilation 45 (95.7) 39 (93) 0.34
Tidal volume, mL/kg (IQR)a 8.6 (7.3-9.9) 7 (6.1-7.9) <0.001
Lowest Pao2/Fio2 ratio (IQR) 101 (80-150) 117 (86-206) 0.17
ARDS 16 (34) 14 (33.3) 1
Renal replacement therapy 34 (72.3) 22 (52.4) 0.08
Antimicrobial treatment
b-lactam 45 (95.7) 41 (97.6) 1
Quinolone 19 (40.4) 12 (25.5) 0.27
Aminoglycoside 23 (49) 22 (52.4) 0.83
Glycopeptide 9 (19.1) 6 (14.3) 0.58
Combination therapy 31 (64) 34 (81) 0.15
Inadequacy of initial antimicrobial treatment 5 (10.6) 3 (7.1) 1
Fluid loading within the first 3 days
Crystalloids, L (IQR) 6 (3-8.9) 3 (1.7-4.5) <0.001
Albumin resuscitation 4 (8.5) 24 (57.1) <0.001
Adjuvant therapies of sepsis
Intensive insulin therapy 15 (31.9) 35 (83.3) <0.001
Low-dose glucocorticoids 21 (44.7) 34 (81) <0.001
Activated protein C 0 2 (4.8) 1
ICU survival 8 (17) 17 (40) 0.02
Hospital survival 3 (6) 12 (29) 0.009
6-month survival 3 (6) 9 (21) 0.06
Variables are expressed as number (percentage) or median (interquartile range (IQR)).
aThe predicted body weight was calculated using the following formulas: 50+0.91 (centimeters of height-152.4) (male patients) or 45.5+0.91(centimeters of
height-152.4) (female patients).
ARDS, Acute Respiratory Distress Syndrome; INR, International Normalized Ratio; MELD, Model for End Stage Liver Disease; SAPS, Simplified Acute Physiology
Score; SOFA, Sequential Organ Failure Assessment.
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P < 0.001, respectively). Only two patients were treated
with drotrecogin alpha (activated) in the recent period.
Short-term and long-term outcomes
The rate of end-of-life decisions was similar between the
two periods (Figure 1). The 6-month vital status was
obtained for all patients. We observed a marked improve-
ment in ICU and hospital survival rates in the recent per-
iod as compared to the 1997-2004 period (40% vs. 17%,
P = 0.02 and 29% vs. 6%, P = 0.009, respectively). Most
importantly, differences in survival occurred early in the
course of the disease (Figure 2A). The benefit in short-
term survival was sustained throughout the first 6 months
following ICU admission (6-month survival rate 21% vs.
6%, P = 0.06) (Figure 2B). Two survivors of the recent
period underwent liver transplantation within 6 months
after ICU admission.
Prognostic factors of hospital mortality
In order to identify the determinants of outcome, we com-
pared the characteristics and treatments of hospital survi-
vors and non-survivors (Table 3). Determinants of hospital
mortality were the stage of the liver disease (Child-Pugh
score, serum protein, and factor V levels), the extent of
organ failures (day-1 SAPS II and SOFA scores, admission
serum lactate level, renal replacement therapy), and admis-
sion during the first period. Finally, we carried out a multi-
variate logistic regression analysis taking into account the
underlying liver disease stage (Child-Pugh score), the criti-
cal illness severity score (for example, SOFA score), and
the recent changes in sepsis management (ICU admission
period). When adjusted for admission SOFA score and
age, the 2005-2010 period remained protective (OR 0.09,
95% CI 0.02-0.4) whereas the stage of cirrhosis prior to
the acute complication was independently associated with
hospital mortality (Child-Pugh score: OR 1.42 per point,
95% CI 1.06-1.9) (Table 4). Similar results were obtained
when adjusted for SAPS II.
Discussion
Septic shock represents a severe complication of cirrhosis
with very low survival rates that question the relevance of
life-sustaining therapies in this subgroup of patients. We
Figure 2 Kaplan Meier estimates of 28-day (A) and 6-month
(B) survival according to the period of admission (1997-2004,
continuous line; 2005-2010, dotted line). Log-rank test: P = 0.02.
Table 3 Determinants of hospital outcome (univariate
analysis).
Variable Deceased
74 patients
Survivors
15 patients
P
Age (IQR) 56 (48-65) 58 (54-62.5) 0.6
Scoring systems (IQR)
Child-Pugh score 10 (8-11) 7 (7-10) 0.05
MELD day 1 25 (18-33.5) 26 (18.5-33.5) 0.19
SAPS II day 1 59 (41.5-83) 50 (42-62.5) 0.02
SOFA day 1 14 (10-17) 9 (7.5-9) 0.03
Biological findings at ICU
admission (IQR)
Arterial blood lactate level,
mmol/l
4.2 (2.1-7.3) 2.8 (2-4.5) 0.08
Serum protein level, g/L 54 (45-62) 62.5 (56-66) 0.06
Factor V, % 41 (27.5-62.5) 53 (48.5-70.5) 0.02
Renal replacement therapy 40 (65%) 5 (36%) 0.02
ARDS 22 (35.5%) 2 (13.5%) 0.08
Albumin resuscitation 24 (32.4) 4 (26.7) 0.77
Low-dose glucocorticoids 44 (59.5 ) 11 (73.3) 0.39
Intensive insulin therapy 39 (52.7) 11 (73.3) 0.16
Admission period
1997-2004 44 (59.5) 3 (20) 0.009
2005-2010 30 (40.5) 12 (80)
Variables are expressed as number (percentage) or median (interquartile
range (IQR)).
ARDS, acute respiratory distress syndrome; MELD, Model For End Stage Liver
Disease; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ
Failure Assessment.
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report here that the current survival rate remains low
but substantially improved over time, suggesting that
advances in care of septic shock extended to this high-
risk subgroup of patients. Most importantly, the short-
term improvement in survival was sustained for at least
6 months, suggesting that ICU admission and extensive
life support is justified in some patients. In addition to
organ failures, the stage of liver disease as assessed by the
Child-Pugh score appears to be an independent prognos-
tic factor that should be taken into account in the deci-
sion-making process.
Cirrhosis is clearly associated with an increased predis-
position to sepsis [4] and has been identified as an inde-
pendent poor prognostic factor in patients with severe
sepsis [24]. In addition, chronic alcohol abuse by itself
may contribute to worsening organ failures and has been
shown to be an independent risk factor of septic shock
[25]. Multiple mechanisms concur to confer an increased
susceptibility to bacterial infections and subsequently to
multiple organ failure in cirrhotic patients. Bacterial trans-
location increases with the severity of liver disease and
represents the main mechanism of spontaneous bacterial
peritonitis. Furthermore, it may sustain the septic process
in every type of infection as suggested by the increased
levels of endotoxin observed in cirrhotic patients [26]. In
addition, innate immune cells display functional abnorm-
alities such as increased production of pro-inflammatory
cytokines in response to LPS [27] or alcohol-induced
defective phagocytosis [28]. As a consequence, plasma
TNF-a and IL-6 levels are higher in cirrhotic patients with
bacterial infection than in non-cirrhotic patients [29].
The overall outcome of severe sepsis and septic shock
has been improved over the last decade concomitant to
the emergence of adjuvant therapeutic interventions such
as early-goal directed therapy [30], protective mechanical
ventilation with low tidal volumes [13], low-dose corticos-
teroids [15], intensive insulin therapy [14], or activated
protein C [16] supported by positive randomized con-
trolled trials. Although the true benefit of some of these
interventions have been addressed by additional studies,
they have been included in the Surviving Sepsis Campaign
guidelines [8]. This international guideline-based perfor-
mance improvement program promoted early recognition
and management of sepsis and showed that increased
compliance with the guidelines was associated with an
improved survival rate [31]. In the same way, a continuous
decrease in the mortality of severe sepsis and septic shock
patients has been reported in large unselected cohorts that
mostly comprised non-cirrhotic patients [1,32,33].
Of note, some significant progress in septic shock has
also been achieved in highly vulnerable subgroups of
patients such as immunocompromised patients with
malignancies [9].
Differences in survival between the two periods occurred
early in the course of the disorder and were thereafter
maintained. The rate of inadequate antibiotic treatment
was low and similar between both periods. Most patients
received an initial combination antimicrobial treatment of
b-lactam associated with either aminoglycosides or fluoro-
quinolones. An initial single dose of aminoglycosides was
commonly subsequently replaced by fluoroquinolones to
limit harmful side-effects. Indeed, some retrospective stu-
dies suggest a benefit of combination antibiotherapy, most
especially of betalactams and aminoglycosides, for septic
shock in general cohorts as well as in cirrhotic patients
[7,34]. Survival improvement was more likely related to
changes in the early management of shock and organ fail-
ures. With respect to fluid resuscitation strategies, the
majority of patients from the recent period received albu-
min and consequently received less crystalloids. Albumin
resuscitation was associated with higher Child-Pugh and
MELD scores (P = 0.04 and P = 0.03 respectively, data not
shown), suggesting that albumin was preferentially indi-
cated to patients with advanced stages of cirrhosis. The
role of albumin resuscitation in sepsis remains challenging.
A meta-analysis suggested that fluid resuscitation with
albumin compared to crystalloids was associated with
improved survival in patients with severe sepsis [35]. Spe-
cifically, albumin resuscitation has been shown to reduce
mortality and renal impairment in cirrhotic patients trea-
ted for spontaneous bacterial peritonitis [36]. Accordingly,
frequent albumin resuscitation in the recent period of our
study was also associated with less frequent recourse to
renal replacement therapy. Altogether, these results and
ours suggest a possible benefit of albumin resuscitation in
cirrhotic patients with severe sepsis, that remains to be
prospectively investigated. The frequent use of low-dose
corticosteroids was also a hallmark of sepsis management
during the second period. Indeed, adrenal dysfunction fre-
quently occurs in patients with septic shock and is asso-
ciated with hemodynamic instability, renal dysfunction,
and increased mortality [37]. However, the use of low-
dose corticosteroids in septic shock remains controversial
because of discrepant efficacy data and a possible higher
risk of nosocomial infections [15]. Of note, this treatment
has been specifically addressed in cirrhotic patients with
septic shock. In a case-control study, resolution of shock
Table 4 Multivariate analysis of factors associated with
in-hospital mortality.
Variable Odds ratio 95% CI P
SOFA (per point) 1.15 0.99-1.32 0.06
Age 1.02 0.96-1.08 0.53
Child-Pugh score (per point) 1.42 1.06-1.9 0.018
Period 2005-2010 (compared
to 1997-2004)
0.09 0.02-0.4 0.004
CI, confidence interval, Goodness of fit (Hosmer-Lemeshow) chi-square
P value = 0.54.
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and survival were higher in hydrocortisone-treated cirrho-
tic patients [38]. However a randomized controlled trial in
septic shock cirrhotic patients was stopped for futility at
interim analysis because hydrocortisone did not reduce
mortality and was associated with an increase in adverse
effects such as shock relapse and gastrointestinal bleeding
[39]. In addition to sepsis-specific therapies, general mea-
sures for ICU patients such as ventilation with low tidal
volumes and glucose control with intravenous insulin
therapy were also routinely implemented during the
second period.
Cirrhotic patients are commonly perceived as poor
candidates for ICU admission because of the very high
mortality rates associated with organ failures [40,41]. A
general improvement in outcome for cirrhotic patients
in the ICU has been recently reported regardless of the
type of acute complication [42,43]. Several factors may
explain this progress, including a better selection of
patients on the basis of previous functional status and
advances in the management of acute complications
such as variceal bleeding [44], hepatorenal syndrome
[45], or septic shock as highlighted in the present study.
The extent of organ failures clearly represents a major
determinant of outcome, and the performance of SOFA
score that nearly reached significance in our multivariate
model is in accordance with previous studies [6,46].
Most importantly, we also identified the stage of the
underlying liver disease assessed by the Child-Pugh
score as an independent prognostic factor of septic
shock. Until now, the discrimination of the Child-Pugh
score calculated at the time of ICU admission had
remained inferior to organ failure scores [6,46,47]. As a
matter of fact, we computed Child-Pugh score prior to
the acute complication in order to reliably assess the
stage of liver disease without any interference from
new-onset organ failures. This finding carries major
practical implications for the decision-making process.
Indeed, this could allow a better selection of patients
likely to benefit from intensive care, on the basis of
underlying disease’s status and realistic therapeutic
options including liver transplantation. Nevertheless, an
accurate individual prognosis prediction of cirrhotic
patients is often difficult at the time of ICU admission,
but can be markedly refined after a few days [6,46]. In
the light of improved outcomes and limited performance
of initial prognostic prediction, critically-ill cirrhotic
patients with a reasonable long-term prognosis should
be offered a broad intensive care access policy with sub-
sequent reappraisal based on the nature of the acute
complication and the evolution of organ failures.
Our study has several limitations that we acknowledge.
First, the design was retrospective despite most data were
prospectively collected through computerized patient
data management system. Therefore, we can only report
an association between changes in care and patient out-
come over the study period. Second, it was carried out in
a single center, with a hepatology unit that is closely
involved in the decision-making process and in the man-
agement of critically ill cirrhotic patients while in the ICU
and after discharge. Third, the limited number of patients
may limit the external validity of our findings. However,
our survival rates in the latter period are similar to those
reported by Arabi et al. (hospital survival 24%) [7] and
Levesque et al. (ICU survival 36%) [6]. Fourth, indications
for ICU admission or end-of-life decisions might have
evolved over the study period, and we cannot exclude that
patients from the recent period were more carefully
selected or referred earlier to the ICU. Nevertheless, the
functional status, the stage of the underlying liver disease
and the severity scores were similar between both periods.
In addition, arterial blood lactate level as an indicator of
prolonged systemic hypoperfusion also suggested similar
duration and severity of shock before ICU admission.
Altogether, these results suggest that improvements in
survival were more likely related to changes in care.
Fourth, we failed to link the recent improvement in survi-
val with a single therapeutic change, suggesting that it is
more likely related to a combination of interventions.
Alternatively, some unrecognized or non-collected data
might also influence the outcome. For instance, the func-
tional status assessed by the performance status prior to
the acute complication is a major prognostic factor in cri-
tically-ill cancer patients [48], and might be more accurate
than the Knaus scale in this setting. In the same way, the
nutritional status might also be of importance in these
patients [49].
Conclusions
This study reports an encouraging improvement in survi-
val in cirrhotic patients with septic shock that needs to be
confirmed in a larger multicenter cohort. Implementation
of therapeutic advances in sepsis probably accounted for
this result. In addition, the stage of the underlying liver
disease appears as an important prognostic factor. Deli-
neation of the long-term prognosis of cirrhosis and the
related therapeutic options thus appears essential in order
to determine the indications for life-sustaining therapies.
Key messages
• The current survival rate of septic shock in cirrho-
tic patients remains low but has improved over the
recent years.
• Cirrhotic patients could have benefited from recent
advances in the management of septic shock.
• The stage of liver disease prior to the acute compli-
cation as assessed by the Child-Pugh score appears to
be an independent prognostic factor of hospital
mortality.
Sauneuf et al. Critical Care 2013, 17:R78
http://ccforum.com/content/17/2/R78
Page 8 of 10
List of abbreviations
ARDS: Acute Respiratory Distress Syndrome; CI: Confidence Interval; COPD:
Chronic Obstructive Pulmonary Disease; ICU: Intensive Care Unit; IL:
Interleukin; INR: International Normalized Ratio; MELD: Model for End-stage
Liver Disease; OR: Odds Ratio; RRT: Renal Replacement Therapy; SAPS:
Simplified Acute Physiology Score; SOFA: Sequential Organ Failure
Assessment; TNF: Tumor Necrosis Factor.
Competing interests
JC is consultant for LFB and received lecture fees. JPM is consultant and
member of the scientific board of LFB, and received lecture fees from LFB,
Fresenius and Baxter. JC and JPM were the main investigators of an
interventional trial on albumin resuscitation in septic shock. FP received
lecture fees from LFB. The authors declare that they have no other
competing interests relevant to the field of the manuscript.
Authors’ contributions
BS, BC, and FP designed the study. BS, BC, AS, and NM extracted the data.
BS and FP performed the statistical analysis. BS, BC, AS, NM, JC, AC, JDC, VM,
JPM, and FP contributed to data analysis. BS and FP drafted the manuscript.
All authors read and approved the final version of the manuscript.
Acknowledgements
Presented at the 40th Congress of the Société de Réanimation de Langue
Française, 18-20 January 2012, Paris, France.
Authors’ details
1Medical intensive care unit, Cochin Hospital, Hôpitaux Universitaires Paris
Centre, Assistance Publique des Hôpitaux de Paris, 27 rue du Faubourg
Saint-Jacques, 75014 Paris, France. 2Université Paris Descartes, Sorbonne Paris
Cité, Faculté de Médecine, 15 rue de l’école de Médecine, 75014 Paris,
France. 3INSERM U970, Paris Cardiovascular Research Center (PARCC),
European Georges Pompidou Hospital, 56 rue Leblanc, 75015 Paris, France.
4Institut Cochin, INSERM U1016, CNRS UMR-8104, 22 rue Méchain, 75014
Paris, France. 5Hepatology unit, Cochin Hospital, Hôpitaux Universitaires Paris
Centre, Assistance Publique des Hôpitaux de Paris, 27 rue du Faubourg
Saint-Jacques, 75014 Paris, France.
Received: 4 November 2012 Revised: 29 January 2013
Accepted: 19 April 2013 Published: 19 April 2013
References
1. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B: Current epidemiology
of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med 2003,
168:165-172.
2. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in
the United States from 1979 through 2000. N Engl J Med 2003,
348:1546-1554.
3. Fernandez J, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V, Rodes J:
Bacterial infections in cirrhosis: epidemiological changes with invasive
procedures and norfloxacin prophylaxis. Hepatology 2002, 35:140-148.
4. Foreman MG, Mannino DM, Moss M: Cirrhosis as a risk factor for sepsis
and death: analysis of the National Hospital Discharge Survey. Chest
2003, 124:1016-1020.
5. Moreau R, Hadengue A, Soupison T, Kirstetter P, Mamzer MF, Vanjak D,
Vauquelin P, Assous M, Sicot C: Septic shock in patients with cirrhosis:
hemodynamic and metabolic characteristics and intensive care unit
outcome. Crit Care Med 1992, 20:746-750.
6. Levesque E, Hoti E, Azoulay D, Ichai P, Habouchi H, Castaing D, Samuel D,
Saliba F: Prospective evaluation of the prognostic scores for cirrhotic
patients admitted to an intensive care unit. J Hepatol 2011, 56:95-102.
7. Arabi YM, Dara SI, Memish Z, Al-Abdulkareem A, Tamim HM, Al-Shirawi N,
Parrillo JE, Dodek P, Lapinsky S, Feinstein D, Wood G, Dial S, Zanotti S,
Kumar A, Cooperative Antimicrobial Therapy of Septic Shock (CATSS)
Database Research Group: Antimicrobial therapeutic determinants of
outcomes in cirrhotic patients with septic shock. Hepatology 2012,
56:2305-2315.
8. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K,
Angus DC, Brun-Buisson C, Beale R Calandra T, Dhainaut JF, Gerlach H,
Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J,
Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL:
Surviving Sepsis Campaign: international guidelines for management of
severe sepsis and septic shock: 2008. Intensive Care Med 2008, 34:17-60.
9. Zuber B, Tran TC, Aegerter P, Grimaldi D, Charpentier J, Guidet B, Mira JP,
Pène F: Impact of case volume on survival of septic shock in patients
with malignancies. Crit Care Med 2012, 40:55-62.
10. Pène F, Percheron S, Lemiale V, Viallon V, Claessens YE, Marque S,
Charpentier J, Angus DC, Cariou A, Chiche JD, Mira JP: Temporal changes
in management and outcome of septic shock in patients with
malignancies in the intensive care unit. Crit Care Med 2008, 36:690-696.
11. Legrand M, Max A, Peigne V, Mariotte E, Canet E, Debrumetz A, Lemiale V,
Seguin A, Darmon M, Schlemmer B, Azoulay E: Survival in neutropenic
patients with severe sepsis or septic shock*. Crit Care Med 2012, 40:43-49.
12. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J,
Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS
International Sepsis Definitions Conference. Intensive Care Med 2003,
29:530-538.
13. The Acute Respiratory Distress Syndrom Network: Ventilation with lower
tidal volumes as compared with traditional tidal volumes for acute lung
injury and the acute respiratory distress syndrome. N Engl J Med 2000,
342:1301-1308.
14. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M,
Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in
the critically ill patients. N Engl J Med 2001, 345:1359-1367.
15. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM,
Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaud P, Bellissant E:
Effect of treatment with low doses of hydrocortisone and
fludrocortisone on mortality in patients with septic shock. JAMA 2002,
288:862-871.
16. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-
Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr:
Efficacy and safety of recombinant human activated protein C for severe
sepsis. N Engl J Med 2001, 344:699-709.
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of
classifying prognostic comorbidity in longitudinal studies: development
and validation. J Chronic Dis 1987, 40:373-383.
18. Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE: APACHE-
acute physiology and chronic health evaluation: a physiologically based
classification system. Crit Care Med 1981, 9:591-597.
19. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R: Transection
of the oesophagus for bleeding oesophageal varices. Br J Surg 1973,
60:646-649.
20. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM,
Kosberg CL, D’Amico G, Dickson ER, Kim WR: A model to predict survival
in patients with end-stage liver disease. Hepatology 2001, 33:464-470.
21. Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology
Score (SAPS II) based on a European/North American multicenter study.
JAMA 1993, 270:2957-2963.
22. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H,
Reinhart CK, Suter PM, Thijs LG: The SOFA (Sepsis-related Organ Failure
Assessment) score to describe organ dysfunction/failure. On behalf of
the Working Group on Sepsis-Related Problems of the European Society
of Intensive Care Medicine. Intensive Care Med 1996, 22:707-710.
23. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC
staging classification. Semin Liver Dis 1999, 19:329-338.
24. Brun-Buisson C, Meshaka P, Pinton P, Vallet B: EPISEPSIS: a reappraisal of
the epidemiology and outcome of severe sepsis in French intensive care
units. Intensive Care Med 2004, 30:580-588.
25. O’Brien JM Jr, Lu B, Ali NA, Martin GS, Aberegg SK, Marsh CB, Lemeshow S,
Douglas IS: Alcohol dependence is independently associated with sepsis,
septic shock, and hospital mortality among adult intensive care unit
patients. Crit Care Med 2007, 35:345-350.
26. Lin RS, Lee FY, Lee SD, Tsai YT, Lin HC, Lu RH, Hsu WC, Huang CC, Wang SS,
Lo KJ: Endotoxemia in patients with chronic liver diseases: relationship
to severity of liver diseases, presence of esophageal varices, and
hyperdynamic circulation. J Hepatol 1995, 22:165-172.
27. Deviere J, Content J, Denys C, Vandenbussche P, Schandene L, Wybran J,
Dupont E: Excessive in vitro bacterial lipopolysaccharide-induced
production of monokines in cirrhosis. Hepatology 1990, 11:628-634.
28. Fiuza C, Salcedo M, Clemente G, Tellado JM: In vivo neutrophil
dysfunction in cirrhotic patients with advanced liver disease. J Infect Dis
2000, 182:526-533.
Sauneuf et al. Critical Care 2013, 17:R78
http://ccforum.com/content/17/2/R78
Page 9 of 10
29. Byl B, Roucloux I, Crusiaux A, Dupont E, Deviere J: Tumor necrosis factor
alpha and interleukin 6 plasma levels in infected cirrhotic patients.
Gastroenterology 1993, 104:1492-1497.
30. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E,
Tomlanovich M: Early goal-directed therapy in the treatment of severe
sepsis and septic shock. N Engl J Med 2001, 345:1368-1377.
31. Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J,
Schorr C, Artigas A, Ramsay G, Beale R, Parker MM, Gerlach H, Reinhart K,
Silva E, Harvey M, Regan S, Angus DC: The Surviving Sepsis Campaign:
results of an international guideline-based performance improvement
program targeting severe sepsis. Crit Care Med 2010, 38:367-374.
32. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL: Rapid increase in
hospitalization and mortality rates for severe sepsis in the United States:
a trend analysis from 1993 to 2003. Crit Care Med 2007, 35:1244-1250.
33. Harrison DA, Welch CA, Eddleston JM: The epidemiology of severe sepsis
in England, Wales and Northern Ireland, 1996 to 2004: secondary
analysis of a high quality clinical database, the ICNARC Case Mix
Programme Database. Crit Care 2006, 10:R42.
34. Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, Laporta D,
Lapinsky S, Ellis P, Mirzanejad Y, Martinka G, Keenan S, Wood G, Arabi Y,
Feinstein D, Kumar A, Dodek P, Kravetsky L, Doucette S, Cooperative
Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group:
Early combination antibiotic therapy yields improved survival compared
with monotherapy in septic shock: a propensity-matched analysis. Crit
Care Med 2010, 38:1773-1785.
35. Delaney AP, Dan A, McCaffrey J, Finfer S: The role of albumin as a
resuscitation fluid for patients with sepsis: a systematic review and
meta-analysis. Crit Care Med 39:386-391.
36. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L,
Vargas V, Soriano G, Guevara M, Ginès P, Rodés J: Effect of intravenous
albumin on renal impairment and mortality in patients with cirrhosis
and spontaneous bacterial peritonitis. N Engl J Med 1999, 341:403-409.
37. Tsai MH, Peng YS, Chen YC, Liu NJ, Ho YP, Fang JT, Lien JM, Yang C,
Chen PC, Wu CS: Adrenal insufficiency in patients with cirrhosis, severe
sepsis and septic shock. Hepatology 2006, 43:673-681.
38. Fernandez J, Escorsell A, Zabalza M, Felipe V, Navasa M, Mas A, Lacy AM,
Gines P, Arroyo V: Adrenal insufficiency in patients with cirrhosis and
septic shock: Effect of treatment with hydrocortisone on survival.
Hepatology 2006, 44:1288-1295.
39. Arabi YM, Aljumah A, Dabbagh O, Tamim HM, Rishu AH, Al-Abdulkareem A,
Knawy BA, Hajeer AH, Tamimi W, Cherfan A: Low-dose hydrocortisone in
patients with cirrhosis and septic shock: a randomized controlled trial.
CMAJ 2010, 182:1971-1977.
40. du Cheyron D, Bouchet B, Parienti JJ, Ramakers M, Charbonneau P: The
attributable mortality of acute renal failure in critically ill patients with
liver cirrhosis. Intensive Care Med 2005, 31:1693-1699.
41. Goldfarb G, Nouel O, Poynard T, Rueff B: Efficiency of respiratory
assistance in cirrhotic patients with liver failure. Intensive Care Med 1983,
9:271-273.
42. O’Brien AJ, Welch CA, Singer M, Harrison DA: Prevalence and outcome of
cirrhosis patients admitted to UK intensive care: a comparison against
dialysis-dependent chronic renal failure patients. Intensive Care Med 2012,
38:991-1000.
43. Galbois A, Trompette ML, Das V, Boelle PY, Carbonell N, Thabut D,
Housset C, Ait-Oufella H, Offenstadt G, Maury E, Guidet B: Improvement in
the prognosis of cirrhotic patients admitted to an intensive care unit, a
retrospective study. Eur J Gastroenterol Hepatol 2012, 24:897-904.
44. Carbonell N, Pauwels A, Serfaty L, Fourdan O, Levy VG, Poupon R:
Improved survival after variceal bleeding in patients with cirrhosis over
the past two decades. Hepatology 2004, 40:652-659.
45. Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P, Abergel A,
Halimi C, Pauwels M, Bronowicki JP, Giostra E, Fleurot C, Gurnot D, Nouel O,
Renard P, Rivoal M, Blanc P, Coumaros D, Ducloux S, Levy S, Pariente A,
Perarnau JM, Roche J, Scribe-Outtas M, Valla D, Bernard B, Samuel D,
Butel J, Hadengue A, Platek A, et al: Terlipressin in patients with cirrhosis
and type 1 hepatorenal syndrome: a retrospective multicenter study.
Gastroenterology 2002, 122:923-930.
46. Das V, Boelle PY, Galbois A, Guidet B, Maury E, Carbonell N, Moreau R,
Offenstadt G: Cirrhotic patients in the medical intensive care unit: early
prognosis and long-term survival. Crit Care Med 2010, 38:2108-2116.
47. Cholongitas E, Senzolo M, Patch D, Shaw S, Hui C, Burroughs AK: Review
article: scoring systems for assessing prognosis in critically ill adult
cirrhotics. Aliment Pharmacol Ther 2006, 24:453-464.
48. Soares M, Caruso P, Silva E, Teles JM, Lobo SM, Friedman G, Dal Pizzol F,
Mello PV, Bozza FA, Silva UV, Torelly AP, Knibel MF, Rezende E, Netto JJ,
Piras C, Castro A, Ferreira BS, Rea-Neto A, Olmedo PB, Salluh JI:
Characteristics and outcomes of patients with cancer requiring
admission to intensive care units: a prospective multicenter study. Crit
Care Med 2010, 38:9-15.
49. Huisman EJ, Trip EJ, Siersema PD, van Hoek B, van Erpecum KJ: Protein
energy malnutrition predicts complications in liver cirrhosis. Eur J
Gastroenterol Hepatol 2011, 23:982-989.
doi:10.1186/cc12687
Cite this article as: Sauneuf et al.: Increased survival of cirrhotic patients
with septic shock. Critical Care 2013 17:R78.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Sauneuf et al. Critical Care 2013, 17:R78
http://ccforum.com/content/17/2/R78
Page 10 of 10
